Global Health Technologies Coalition Global Health Technologies Coalition
  • Why R&D
  • R&D Facts
  • In Your State
  • Solutions
  • Breakthroughs Blog
  • News & Events
  • Resources
  • About Us
Stay Informed

Global health R&D delivers forAlabama

Map
Alabama
Select a new state
Select a State
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois
Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana
Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island
South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

US government investment in global health R&D has delivered

$68.7 million
to Alabama research institutions
850+ new jobs
for Alabama
Alabama

Neglected diseases in Alabama

Chikungunya cases
Chikungunya cases
22
Dengue cases
Dengue cases
39
HIV diagnoses
HIV diagnoses
5943
Malaria cases
Malaria cases
66
Tuberculosis cases
Tuberculosis cases
1257
West Nile cases
West Nile cases
127
Zika cases
Zika cases
40
Alabama's top USG-funded global health R&D institutions

Alabama's top USG-funded global health R&D institutions

University of Alabama at Birmingham
$53.3 million
Southern Research Institute
$14.1 million
Auburn University
$876 thousand
Alabama State University
$341 thousand
Alabama industry in global health R&D

Alabama industry in global health R&D

CNine Biosolutions
Location(s): Birmingham
Biocryst Pharmaceuticals
Location(s): Birmingham

Alabama's top areas of global health R&D by USG funding

61.6%
HIV/AIDS
2.4%
Malaria
21.7%
Tuberculosis
6.6%
Bacterial pneumonia & meningitis
3.4%
Neglected tropical diseases
Dengue
Kinetoplastids
Trachoma
4.2%
Other
Diarrheal diseases
Ebola/viral hemorrhagic fevers
Hepatitis C
Non-allocable
Rheumatic fever
Global health R&D at work in Alabama
Global health R&D at work in Alabama

The University of Alabama at Birmingham School of Medicine operates the Antiviral Drug Discovery and Development Center (AD3C), funded by the US National Institutes of Health. AD3C focuses on developing drug therapies for diseases such as influenza, West Nile virus, SARS, chikungunya, and dengue. Researchers work to target and inhibit enzymes essential for viral replication. The viruses AD3C targets are of high priority for the US government as the global burden of these diseases is enormous, with West Nile virus and influenza routinely infecting US citizens. Southern Research Institute in Birmingham is supporting AD3C in screening potential compounds.

Download PDF
Map
Select a new state
Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: NIAID
Close
advancing innovation to save lives

© 2009–2021, PATH, as secretariat of the Global Health Technologies Coalition.

  • Stay Informed
  • Join Us
  • Contact Us
  • GHTC Member Log In